Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Today, the Company has approximately 30 programmes in the pipeline and six Nanobodies are at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
